FDA Drug Topics: FDA’s Role in Postmarketing Drug Safety Surveillance - September 28, 2021
FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) is excited to present a series of educational webinars targeting the needs of all health care professionals and students, including physicians, physician assistants, nurses, pharmacists, and pharmacy technicians. Interact with FDA staff from a variety of divisions and learn more about the FDA and drug regulation!
On Tuesday, September 28, 2021, CDER's Office of Communication, Division of Drug Information (DDI) hosted a webinar titled: FDA Drug Topics: FDA’s Role in Postmarketing Drug Safety Surveillance. This webinar provided an overview on how the FDA conducts postmarketing drug safety surveillance at the Center for Drug Evaluation and Research (CDER). We discussed how adverse event reports are collected, analyzed, and communicated to the public.
View Presentation Here: https://collaboration.fda.gov/piznwya2xf1c/
Download Presentation Slides: FDA’s Role in Postmarketing Drug Safety Surveillance (PDF - 1.82MB)
Activity Outline and Continuing Education Information: FDA’s Role in Postmarketing Drug Safety Surveillance (PDF - 156KB)
If you have never attended an Adobe Connect meeting before (Google Chrome (preferred) or Firefox 43 or higher):
Test your connection: Adobe Connect Diagnostic Test
Get a quick overview: Discover Adobe Connect Solutions
Adobe, the Adobe logo, Acrobat and Adobe Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.